Nirmatrelvir/ritonavir for COVID-19: an overview of systematic reviews
Description
CONCLUSIONS: There is low to moderate certainty of evidence from SRs that nirmatrelvir/ritonavir reduces mortality, clinical progression and hospitalization rate in COVID-19 patients compared with controls, without increasing the occurrence of
